MeSH term
Frequency | Condition_Probility | Female | 20 | 0.0 |
Humans | 61 | 0.0 |
Male | 21 | 0.0 |
Microbial Sensitivity Tests | 2 | 0.0 |
Middle Aged | 15 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 39 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 10 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Animals | 23 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Immunohistochemistry | 19 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Swine | 3 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Cattle | 3 | 0.0 |
Potassium Channel Blockers/pharmacology | 2 | 6.0 |
Aged | 13 | 0.0 |
English Abstract | 6 | 0.0 |
Radioimmunoassay | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Organ Specificity | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Cryptococcus neoformans/*classification/isolation & purification | 3 | 100.0 |
Serotyping | 6 | 2.0 |
Binding Sites | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Chromogranins/analysis | 2 | 3.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Somatostatin/analysis | 2 | 3.0 |
Dimerization | 2 | 0.0 |
Base Sequence | 3 | 0.0 |
Comparative Study | 10 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Rats | 8 | 0.0 |
Adolescent | 6 | 0.0 |
Child | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
Infant | 2 | 0.0 |
Cytoplasmic Granules/*metabolism | 2 | 8.0 |
Exons | 2 | 0.0 |
Culture Media | 4 | 0.0 |
Protein Conformation | 2 | 0.0 |
Adult | 12 | 0.0 |
Chronic Disease | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Mice | 4 | 0.0 |
Feces/microbiology | 2 | 3.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Random Amplified Polymorphic DNA Technique | 2 | 8.0 |
Catecholamines/secretion | 2 | 40.0 |
PC12 Cells | 4 | 1.0 |
Aged, 80 and over | 6 | 0.0 |
Cell Transformation, Neoplastic/pathology | 2 | 4.0 |
Prognosis | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Chromogranins/*blood | 2 | 3.0 |
*Proteins | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Thyrotropin/analysis | 2 | 16.0 |
Sensitivity and Specificity | 2 | 0.0 |
Chromogranins/*analysis | 2 | 5.0 |
Staining and Labeling | 2 | 0.0 |
Chromogranins/*metabolism | 4 | 17.0 |
Gene Expression | 3 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Cyanogen Bromide | 2 | 3.0 |
Adenoma/*pathology | 2 | 9.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Chickens | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Argentina/epidemiology | 2 | 13.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
